QR Pharma is a specialty pharmaceutical company founded to develop novel treatments for Parkinson's disease (PD) and other neurodegenerative disorders. The company's lead asset is Posiphen which targets early stage PD and may stop or slow the progression of the disease.
Posiphen reduces levels of amyloid precursor protein (APP), tau and
α-Synuclein (aSYN), three proteins that can turn toxic and precipitate the onset of neurodegeneration. Posiphen inhibits APP, tau and aSYN in tissue culture cells, mice as well as in humans.
Posiphen also shows promise in Huntington's disease, Down Syndrome, Traumatic Brain Injury, Post Operative Cognitive Decline and Alzheimer's disease.
QR's second drug is BNC which targets late stage Alzheimer's disease.
The economic burden and impact on wellness and quality of life for both patients and their caregivers of Parkinson's and these other neurodegenerative disease is crushing. Today, existing drugs manage the symptoms and provide only marginal cost-benefit tradeoffs. QR seeks to develop drugs that stop the progression of these diseases.